After a two-year, randomized, control study of 2,000+ RRMS patients, drugmaker Novartis announced promising findings. Patients taking a once-daily oral dose of fingolimod saw a decrease of almost half in annual relapse rates of RRMS. This reduction in attacks resulted in patients with a better-functioning nervous system than the unmedicated control. In addition, the...
Recent Comments